Abstract: An aromatic polyanhydride having a repeating unit with structure (I) wherein Ar is a substituted or unsubstituted aromatic ring and R is a difunctional organic moiety substituted on each Ar ortho to the anhydride group. Ortho-substituted bis-aromatic dicarboxylic acid anhydride monomers and ortho-substituted bis-aromatic dicarboxylic acid intermediates thereof are also disclosed, as well as implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic oral dosage forms and treatment methods.
Type:
Grant
Filed:
September 10, 1998
Date of Patent:
October 17, 2006
Assignee:
Rutgers, The State University of New Jersey
Abstract: The present invention provides modified fibronectin type III (Fn3) molecules, nucleic acid molecules encoding the modified Fn3 molecules, and related vectors and host cells.
Abstract: Systems and methods are provided through which a model-based vision system for dentistry which assists in diagnosis, treatment planning and surgical simulation. The present invention includes an integrated computer vision system that constructs a three-dimensional (3-D) model of the patient's dental occlusion using an intra-oral video camera. A modified shape from shading technique, using perspective projection and camera calibration, extracts the 3-D information from a sequence of two-dimensional images of the jaw. Data fusion of range data and 3-D registration techniques develop a complete 3-D digital jaw model. Triangulation of the 3-D digital model is then performed, and optionally, a solid 3-D model is reconstructed.
Type:
Grant
Filed:
April 26, 2001
Date of Patent:
August 1, 2006
Assignee:
University of Louisville Research Foundation, Inc.
Inventors:
Aly A. Farag, David Tasman, Sameh M. Yamany
Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding a monobody, and a variegated nucleic acid library encoding a monobody, are provided by the invention. Also provided are methods of preparing an Fn3 polypeptide monobody, and kits to perform such methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.
Abstract: The invention provides compounds of formula I: wherein A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.
Type:
Grant
Filed:
May 14, 2004
Date of Patent:
May 23, 2006
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Edmond J. LaVoie, Alexander L. Ruchelman, Leroy F. Liu
Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.
Type:
Grant
Filed:
November 27, 1996
Date of Patent:
February 28, 2006
Assignees:
University of Iowa Research Foundation, The Regents of the University of California
Inventors:
Michael A. Apicella, Melvin G. Sunshine, Na-Gyong Lee, Bradford W. Gibson, Rasappa Arumugham
Abstract: The invention provides compounds of formula I: wherein R1-R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer and infections using compounds of formula I.
Type:
Grant
Filed:
August 11, 2003
Date of Patent:
January 31, 2006
Assignee:
Rutgers, The University of New Jersey
Inventors:
Edmond J. LaVoie, Alexander L. Ruchelman, Leroy F. Liu
Abstract: The invention provides compounds of formula I: wherein: R1-R5, “a” and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.
Type:
Grant
Filed:
August 11, 2003
Date of Patent:
January 31, 2006
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Edmond J. LaVoie, Sudhir K. Singh, Leroy F. Liu
Abstract: The invention provides compounds of formula I: wherein R1–R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.
Type:
Grant
Filed:
August 11, 2003
Date of Patent:
January 24, 2006
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Edmond J. LaVoie, Sudhir K. Singh, Leroy F. Liu
Abstract: The invention provides secondary sulfonamide polymers, wherein some, most, or all of the sulfonamido protons have been replaced with a substituent other than hydrogen. The invention also provides methods for preparing such polymers as well as devices (e.g. composite membranes) incorporating such membranes.
Type:
Grant
Filed:
November 22, 2002
Date of Patent:
January 17, 2006
Assignee:
Osmonics, Inc.
Inventors:
Christopher J. Kurth, Steven D. Kloos, Jessica A. Peschl, Leonard T. Hodgins
Abstract: The invention provides compounds of formula I: wherein A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.
Type:
Grant
Filed:
May 14, 2004
Date of Patent:
January 17, 2006
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Edmond J. LaVoie, Alexander L. Ruchelman
Abstract: The invention provides compounds of formula I: wherein A, B, W, Y, Z, R1, R3 and R4 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.
Type:
Grant
Filed:
May 14, 2004
Date of Patent:
November 15, 2005
Assignee:
Rutgers The State University of New Jersey
Inventors:
Edmond J. LaVoie, Alexander L. Ruchelman